A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naive Metastatic Hormone Refractory Prostate Cancer (HRPC).
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2011
At a glance
- Drugs AT 101; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 19 Feb 2011 Results presented at the 2011 Genitourinary Cancers Symposium.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History